InfuSystem Holdings Files 8-K for Regulation FD Disclosure
Ticker: INFU · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1337013
| Field | Detail |
|---|---|
| Company | Infusystem Holdings, INC (INFU) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
InfuSystem Holdings filed an 8-K for a Reg FD disclosure. Details TBD.
AI Summary
InfuSystem Holdings, Inc. filed an 8-K on August 6, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or details about the nature of the disclosure, only that it is a current report.
Why It Matters
This filing indicates InfuSystem Holdings is making a public disclosure under Regulation FD, which could contain material information for investors.
Risk Assessment
Risk Level: medium — The filing itself is procedural, but the lack of immediate detail on the Regulation FD disclosure warrants a medium risk assessment until the content is understood.
Key Players & Entities
- InfuSystem Holdings, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of Report
- Rochester Hills, Michigan (location) — Principal Executive Offices
FAQ
What is the specific nature of the Regulation FD Disclosure being made by InfuSystem Holdings, Inc.?
The provided 8-K filing does not specify the content of the Regulation FD Disclosure, only that one is being made on August 6, 2024.
When was this 8-K filing submitted to the SEC?
The filing was submitted on August 6, 2024.
What is the principal executive office address for InfuSystem Holdings, Inc.?
The principal executive offices are located at 3851 West Hamlin Road, Rochester Hills, Michigan 48309.
What is the Commission File Number for InfuSystem Holdings, Inc.?
The Commission File Number is 001-35020.
Has InfuSystem Holdings, Inc. had previous company names?
Yes, the company was formerly known as HAPC, Inc. (name change effective April 25, 2006) and Healthcare Acquisition Partners Corp. (name change effective August 24, 2005).
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-06 06:30:28
Filing Documents
- infu-20240806.htm (8-K) — 28KB
- exhibit99108-06x2024smithn.htm (EX-99.1) — 15KB
- infusystem_safesmarttruste.jpg (GRAPHIC) — 760KB
- 0001628280-24-034940.txt ( ) — 1206KB
- infu-20240806.xsd (EX-101.SCH) — 2KB
- infu-20240806_lab.xml (EX-101.LAB) — 21KB
- infu-20240806_pre.xml (EX-101.PRE) — 12KB
- infu-20240806_htm.xml (XML) — 3KB
01 - Regulation FD Disclosure
Item 7.01 - Regulation FD Disclosure On August 6, 2024, InfuSystem Holdings, Inc. (the "Company") issued a press release announcing a three-year distribution agreement with Smith+Nephew for its innovative negative pressure wound therapy system and supplies. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01 — "Regulation FD Disclosure" of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of InfuSystem Holdings, Inc. dated August 6 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INFUSYSTEM HOLDINGS, INC. By: /s/ Barry Steele Barry Steele Chief Financial Officer Dated: August 6, 2024